Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Qiong J. Wang"'
Autor:
Linchun Jin, Haipeng Tao, Aida Karachi, Yu Long, Alicia Y. Hou, Meng Na, Kyle A. Dyson, Adam J. Grippin, Loic P. Deleyrolle, Wang Zhang, Didier A. Rajon, Qiong J. Wang, James C. Yang, Jesse L. Kresak, Elias J. Sayour, Maryam Rahman, Frank J. Bova, Zhiguo Lin, Duane A. Mitchell, Jianping Huang
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-13 (2019)
CAR T-cell therapy efficacy in solid tumors is limited by inadequate T-cell migration and/or persistence in tumour microenvironment. Here, the authors show that the activity of tumour-antigen specific CAR T cells, in multiple preclinical mouse models
Externí odkaz:
https://doaj.org/article/de9a908e5e6e46b0b45bc79a9225470e
(A) mTCR Expression of human PBL co-transduced with oligoclonal TCR alpha and beta chains. (B) Reactivity of PBL co-transduced with oligoclonal TCR alpha and beta chains. (C) Correlation between KRAS G12D expression and reactivity of KRAS G12D-reacti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a4382db22c0ddc47869ba005c64fa90
https://doi.org/10.1158/2326-6066.22537930
https://doi.org/10.1158/2326-6066.22537930
KRAS is one of the most frequently mutated proto-oncogenes in human cancers. The dominant oncogenic mutations of KRAS are single amino acid substitutions at codon 12, in particular G12D and G12V present in 60% to 70% of pancreatic cancers and 20% to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c20df94de0ce68a2d35a2acd5980b0b1
https://doi.org/10.1158/2326-6066.c.6548608.v1
https://doi.org/10.1158/2326-6066.c.6548608.v1
Supplementary Table 1: Predicted HLA-binding affinity of mutated KRAS G12D and KRAS G12V.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3fa431d75731915fc6fc3c6fbc532e61
https://doi.org/10.1158/2326-6066.22537927
https://doi.org/10.1158/2326-6066.22537927
Autor:
James C. Yang, Nicholas P. Restifo, David Kleiner, Krishna Patel, Ken-ichi Hanada, Zhiya Yu, Qiong J. Wang
Supplementary Figure 1. CD70 expression on tumor lines Supplementary Figure 2. In vivo persistence of transferred murine T cells. Body weight and cell counts of non-tumor bearing mice.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42e92d83fb900269315dcdf2224d22d3
https://doi.org/10.1158/1078-0432.22465019.v1
https://doi.org/10.1158/1078-0432.22465019.v1
Autor:
James C. Yang, Nicholas P. Restifo, David Kleiner, Krishna Patel, Ken-ichi Hanada, Zhiya Yu, Qiong J. Wang
Purpose: CD70 expression in normal tissues is restricted to activated lymphoid tissues. Targeting CD70 on CD70-expressing tumors could mediate “on-target, off-tumor” toxicity. This study was to evaluate the feasibility and safety of using anti-hu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9690d8675b8eaf9d1b618d92e1e4ecb1
https://doi.org/10.1158/1078-0432.c.6525899
https://doi.org/10.1158/1078-0432.c.6525899
Autor:
James C. Yang, Nicholas P. Restifo, David Kleiner, Krishna Patel, Ken-ichi Hanada, Zhiya Yu, Qiong J. Wang
HLA Genotyping of renal cell cancer cell lines
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a2bf0b07dab61d898a8ecf6adca2c5b
https://doi.org/10.1158/1078-0432.22465016
https://doi.org/10.1158/1078-0432.22465016
PDF file - 30K, Correlation between CD70 expression (Mean fluorescence intensity; MFI) and RCC T cell phenotype. T cells from renal tumors were labeled the same as shown in Figure 1, and Lin 1- cells from renal tumors were labeled the same as shown i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24b695a9cb3f9b38cee43e29e9344f45
https://doi.org/10.1158/0008-5472.22392224.v1
https://doi.org/10.1158/0008-5472.22392224.v1
PDF file - 58K, HLA-class II expression of RCC tumor lines with or without CIITA transduction. Tumor lines were labeled with isotype control (open histograms) or anti-HLA DR Ab (filled histograms) and analyzed on FACSCantoII
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::500a282ffde05556580b8c2eccd9ab64
https://doi.org/10.1158/0008-5472.22392221
https://doi.org/10.1158/0008-5472.22392221
Autor:
Frank J. Bova, Jesse Kresak, Linchun Jin, Adam Grippin, Qiong J. Wang, Yu Long, Jianping Huang, Alicia Y Hou, Meng Na, Aida Karachi, James Chih-Hsin Yang, Didier A. Rajon, Maryam Rahman, Loic P. Deleyrolle, Elias Sayour, Duane Mitchell, Haipeng Tao, Wang Zhang, Zhiguo Lin, Kyle Dyson
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-13 (2019)
Nature Communications
Nature Communications
Chimeric antigen receptor (CAR) T-cell therapy targeting solid tumors has stagnated as a result of tumor heterogeneity, immunosuppressive microenvironments, and inadequate intratumoral T cell trafficking and persistence. Early (≤3 days) intratumora
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2cb4f8a686f29405567b1fda2109954a
https://doaj.org/article/de9a908e5e6e46b0b45bc79a9225470e
https://doaj.org/article/de9a908e5e6e46b0b45bc79a9225470e